Stifel upgrades Tandem Diabetes to Buy and raises price target to $26

Stifel Securities lifted its rating on Tandem Diabetes Care to Buy from Hold and increased its price target to $26, up from $22. The firm noted improving margins, a stronger product pipeline and recent FDA clearance for the Tandem Mobi tubeless insulin delivery system. The stock was trading around $17.06 at the time of the upgrade.

Stifel’s upgrade and higher price target suggest roughly 50% upside, which could attract buying interest and lift the share price. The analyst’s view is reflected in the pre‑market rally of about 5‑6% following the note.

  • 1Stifel upgraded Tandem Diabetes Care to Buy from Hold.
  • 2Stifel raised its price target to $26, up from $22.
  • 3The stock was trading at $17.06 when the upgrade was announced.
  • 4Tandem Diabetes received 510(k) clearance from the FDA for its Tandem Mobi tubeless insulin delivery system.

Sources